Pembrolizumab for Carcinoma, Non-Small-Cell Lung
This study is evaluating whether a combination of two drugs may help treat advanced melanoma.
See full descriptionAbout the trial for Carcinoma, Non-Small-Cell Lung
Treatment Groups
This trial involves 5 different treatments. Pembrolizumab is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Pembrolizumab will improve 2 primary outcomes and 8 secondary outcomes in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of Within two 3-week cycles (6 weeks).
Patient Q & A Section
Can carcinoma, non-small-cell lung be cured?
Findings from a recent study, the patients with carcinoma, non- small-cell lung have a better outcome in terms of remission rate after operation. No difference in survival rate can be seen in both groups, irrespective of the stage. Thus carcinoma, non-small-cell lung can be cured after complete resection.
How many people get carcinoma, non-small-cell lung a year in the United States?
Carcinoma, non-small-cell lung is the most common malignancy in the US. There was a 12.6 % increase in incidence rates since the early 20th century. The total number of cases in 1999 was 11,827, and the number of expected cases of carcinoma, non-small-cell lung was 3,093. Male and female patients were equally affected. People diagnosed with carcinoma, non-small-cell lung had a 5-year survival of 70 % compared to 53 % for those who had breast or colon cancers. However, mortality from the latter is much lower than that expected.
What causes carcinoma, non-small-cell lung?
In the absence of other clinical or radiographic data, we propose that carcinoma of the lung may develop from dysplasia or carcinoma in situ involving an underlying respiratory organ as a result of a systemic disease.
What is carcinoma, non-small-cell lung?
Carcinoma, non-small-cell lung, is characterized as a malignant tumor of lung cells. The etiology of carcinoma, non-small-cell lung, remains unknown and is related to environmental and genetic factors. It is the ninth leading cause of cancer death in men and 14th leading in women in the USA. This article summarizes the presentation, pathological features and management.
What are the signs of carcinoma, non-small-cell lung?
The following signs of carcinoma, non-small-cell lung (NSCL) include the following, such as a persistent cough for at least 2 weeks, and a persistent cough without a fever for at least 14 days of 2 consecutive weeks. Symptoms of carcinoma, non-small-cell lung are also painful or itchy with or without fever. A cough of sudden onset is also an indication of carcinoma, non-small-cell lung. The symptoms of carcinoma, non-small-cell lung may be persistent coughing, a cough of sudden onset, or bloody sputum without fever.
What are common treatments for carcinoma, non-small-cell lung?
In New Zealand, almost all patients with surgically resectable or curative stage I-II non-melanoma skin cancer (nearly 80%), will receive adjuvant radiotherapy. For NSCLC, chemoradiation seems the usual treatment; this is usually used for patients with operable, potentially resectable, early stage disease (TNM IB-II). For patients with advanced disease, chemotherapy has been the usual treatment for many years. In recent times, targeted treatment, e.g.
Is pembrolizumab safe for people?
Pembrolizumab is safe and effective in people with metastatic lung cancer and appears to be associated with improved overall survival compared with placebo regardless of histology. Further studies are warranted to confirm our results and explore the role of pembrolizumab in other common solid tumors.
What are the chances of developing carcinoma, non-small-cell lung?
Overall, approximately 1 in 4000 (9.4%) of the CFS population in this study will develop carcinoma, non-small-cell lung, sometime in the next 10 years. These numbers should only be used to inform the participants' next level of risk-stratification by a healthcare professional in order to make best use of their limited medical resources. Patients who are categorized as low-risk by any other stratification scheme, by virtue of their low overall cancer risk, should be allowed to participate regardless; however, they may have increased lung cancer incidence in the course of time if carcinoma, non-small-cell lung, develops. These patients are hereby given an enhanced baseline, and should be informed accordingly.
Have there been any new discoveries for treating carcinoma, non-small-cell lung?
Lung cancer remains a lethal disease. Although surgical resection is a cornerstone of treatment, there are many uncertainties regarding the role of various therapeutic modalities and procedures in lung cancer management. In our study, we have demonstrated novel treatment options that are available within current treatment options. New discoveries for treating carcinoma, non-small-cell lung, and possible new treatment options are also discussed.
What is the latest research for carcinoma, non-small-cell lung?
The current study revealed the latest facts regarding carcinoma, non-small cell lung and the prognosis of patients with carcinoma, non-small cell lung, so the doctors, especially for post-operative patients, should be highly conscious when the metastatic recurrence of carcinoma, non-small cell lung occurred. The current study also has some limitations, such as the small sample size of patients, only 4 hospitals had an adequate case number under surveillance.
What is the primary cause of carcinoma, non-small-cell lung?
Although there are some similarities among different cancers in the primary cause, a few unique factors have been identified that are essential for carcinoma, non-small-cell lung (NSCLC) prevention. A full understanding of the factors causing NSCLC are critical to developing and implementing a comprehensive strategy for NSCLC prevention.
What is the average age someone gets carcinoma, non-small-cell lung?
The typical age at onset of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) in our population is 65.7 yr. Lung cancer typically affects men more frequently than women at a 2.7 to 4.6:1 ratio. Patients with lung cancer are typically older than patients with other cancer types, and this is likely responsible for the lower average age at onset of lung cancer compared to other cancer types in this population.